StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) income statement

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.10−0.55 (-9.73%)

Close on Nov 18, 2026Market cap $9.82MP/E –Yield –

Bolt Biotherapeutics, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-1098.0%
Net margin
-1034.4%
Return on equity, FY2025
-79.7%

Financial strength

Current ratio
2.05
Debt to equity
–
Debt to assets
–
Cash to current liabilities
165.7%

Valuation

P/E ratio
–
Price to sales
3.88
Price to book
1.15
Dividend yield
–

See a number that looks wrong?